Structure Therapeutics Inc.

NASDAQ:GPCR

Biotechnology

Healthcare
$17.36 +0.86%

+$0.39 today

Market cap
$999.36M
Beta
-1.42
P/E (TTM)
-19.3
EPS (TTM)
-$2.35
52W Low $15.80High $94.90

Volume 1.10M

Average 0.87M

GPCR Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Structure Therapeutics Inc.NASDAQ: GPCR

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit remains negative

Q2 FY2026 gross profit was $0, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$1.22M.

Context

  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$304.66K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$3.9M— YoY
LTMJun 2026
-$1.22M— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(3.9M) USD
Year-over-year change
—

Gross Profit vs competitors

How GPCR compares with its peers on the latest reported figures

  • GPCR's LTM Jun 2026 gross profit of -$1.22M is the lowest of the 8 companies compared; the peer median is $10.25M.
GPCR Competitors Peer median
Gross Profit for GPCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SEPNSepterna, Inc.LTM Sep 2026$76.97M +249.1%—79.9%
VTVTvTv Therapeutics Inc.LTM Mar 2026$36.84M +736860.0%—100.0%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$18.41M -89.0%—92.0%
BIOABioAge Labs, Inc.LTM Mar 2026$10.25M +606.6%—99.4%
KLRAKailera Therapeutics, Inc.FY2025$0 ———
MLYSMineralys Therapeutics, Inc.LTM Jun 2026-$21K ———
BMEABiomea Fusion, Inc.LTM Mar 2026-$593K ———
GPCRStructure Therapeutics Inc.LTM Jun 2026-$1.22M ———
Peer median (excluding GPCR) $10.25M+427.9%—95.7%

Competitors are the stored peer set for GPCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00003.9M
Gross Profit0000(3.9M)
Gross Margin—————
Research & Development29.11M36.19M70.1M108.81M225.26M
Selling, General & Admin8.59M16.37M32.67M49.41M61.55M
Operating Expenses37.7M52.56M102.78M158.23M283.67M
Depreciation & Amortization72K277K295K992K3.9M
EBITDA(37.62M)(51.03M)(75.7M)(121.22M)(136.79M)
EBITDA Margin—————
Operating Income(37.7M)(52.56M)(102.78M)(158.23M)(287.57M)
Operating Margin—————
Interest Income1221.26M13.38M36.03M35.97M
Interest Expense122.16K013.39M00
Other Income / Expenses(122K)1.26M13.39M36.01M146.51M
Income Before Tax(37.82M)(51.3M)(89.38M)(122.22M)(140.69M)
Pre-Tax Margin—————
Income Tax Expense231K17K236K310K515K
Net Income(40.01M)(51.32M)(89.62M)(122.53M)(141.2M)
Net Margin—————
EPS (Basic)(1.20)(1.44)(2.43)(2.34)(2.40)
EPS (Diluted)(1.20)(1.44)(2.43)(2.34)(2.40)
Weighted Avg Shares36.59M36.59M36.73M52.64M59.2M
Weighted Avg Shares (Diluted)36.59M36.59M36.73M52.64M59.2M

Structure Therapeutics Inc.

NASDAQ:GPCR

Intrinsic Alpha fair value

Locked

Current Price

$17.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.